Information That Can Help Define Treatment Options and Make Treatment Decisions for Breast (early-stage and DCIS) and Colon Cancer Patients
About the Oncotype DX Breast Cancer Test and Early Stage Breast Cancer
The Oncotype DX breast cancer assay, is a test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about a patient's individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
Oncotype DX Breast Cancer Test Evaluation and Impacts on Breast Cancer Treatment Options
The Oncotype DX breast cancer multigene expression test has been extensively evaluated in 14 clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.
Oncotype DX is the only test incorporated in published ASCO® and NCCN® breast cancer treatment guidelines for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For complete information on Oncotype DX for Patients & Caregivers, Healthcare Providers, and Managed Care Organizations, visit Oncotype DX.com.
For additional information for Patients & Caregivers and detail about breast cancer treatment options, visit MyBreastCancerTreatment.org.
About the Oncotype DX Breast Cancer Test for DCIS (Ductal Carcinoma In Situ) and Pre-Invasive Breast Cancer
The Oncotype DX® Breast Cancer test for DCIS patients is the first clinically validated genomic assay to provide an individualized prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma) to help guide treatment decision-making in women with ductal carcinoma in situ treated by local excision, with or without tamoxifen. Learn more about this new test for DCIS patients.
About the Oncotype DX Colon Cancer Test and Stage II Colon Cancer
The Oncotype DX colon cancer assay is a colon cancer test that provides an individual, numerical assessment of how likely colon cancer is to return in patients with stage II colon cancer following surgery to remove the tumor. The multigene expression assay examines the activity of specific genes within a patient´s tumor sample in order to provide individualized information to each person and their physician about the specific biological make-up of their colon cancer.
The Oncotype DX assay is appropriate for people who are newly diagnosed with stage II colon cancer and is performed on tumor tissue removed during the original surgery. Because of this, the Oncotype DX assay does not require any additional surgery or procedures in order for a patient to get the test.
For detailed information about Oncotype DX, please call: (866) ONCOTYPE or visit www.oncotypedx.com.
Watch videos about the gene expression assay online.
Patient Stories provide detailed information about patients' experiences with Oncotype DX assays.
Learn more about Genomic Health’s products in development:
ASCO® is a registered trademark of the American Society of Clinical Oncology. NCCN® is a registered trademark of the National Comprehensive Cancer Network. ASCO and NCCN do not endorse any product or therapy.